Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.

Abbisko Cayman Limited
和譽開曼有限責任公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT
THE LANCET PUBLISHES GLOBAL PHASE 3 MANEUVER STUDY RESULTS OF PIMICOTINIB

Abbisko Cayman Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**"), a subsidiary of the Company, announced that data from the global multicenter Phase 3 MANEUVER study of pimicotinib (ABSK021), a novel, oral, highly selective and potent small-molecule CSF-1R inhibitor developed in-house by Abbisko, have been published on March 5, WET in the international medical journal *The Lancet*[1]. This publication marks a significant milestone for Abbisko in terms of clinical research quality, data integrity, and international academic recognition for this innovative therapy.

This is a voluntary announcement made by the Company. The Group cannot guarantee that pimicotinib will ultimately be successfully commercialized. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, 9 March 2026

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Ji Jing as executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Ms. Chui Hoi Yam as independent non-executive directors.

The Lancet Publishes Global Phase 3 MANEUVER Study Results of Pimicotinib

On 9 March 2026, Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**") announced that data from the global multicenter Phase 3 MANEUVER study of pimicotinib (ABSK021), a novel, oral, highly selective and potent small-molecule CSF-1R inhibitor developed in-house by Abbisko, have been published on March 5, WET in the international medical journal *The Lancet*[1]. This publication marks a significant milestone for Abbisko in terms of clinical research quality, data integrity, and international academic recognition for this innovative therapy.

The MANEUVER study enrolled 94 patients across more than 30 clinical centers worldwide, with patients from outside China accounting for more than half of the study population. The data show that pimicotinib achieved significant efficacy along with a generally favorable safety profile in patients with tenosynovial giant cell tumor ("**TGCT**")[2].

Pimicotinib, for which Merck holds worldwide commercialization rights, received approval from the China National Medical Products Administration ("**China NMPA**") in December 2025 for the treatment of adult patients with symptomatic TGCT for which surgical resection will potentially cause functional limitation or relatively severe morbidity[3]. Meanwhile, a New Drug Application ("**NDA**") has been formally accepted by the U.S. Food and Drug Administration ("**US FDA**"), and additional applications are under review by regulatory bodies in other markets.

References

1 Xu H, Niu X, Ravi V, et al. Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial. Lancet. Published online 2026.

2 Xiaohui Niu et al. Pimicotinib in tenosynovial giant cell tumor (TGCT): Efficacy, safety and patient-reported outcomes of phase 3 MANEUVER study. J Clin Oncol 43, 11500-11500(2025).

3 https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20251222123420165.html

About Pimicotinib

Pimicotinib is a novel, oral, highly selective, and potent small-molecule CSF-1R inhibitor independently developed by Abbisko Therapeutics. Positive topline results from the global Phase 3 MANEUVER study of pimicotinib for the treatment of TGCT were announced in November 2024. Currently, pimicotinib has been approved by the China NMPA for the treatment of adult patients with symptomatic TGCT for which surgical resection will potentially cause functional limitation or relatively severe morbidity. In December 2023, Abbisko entered into an agreement with Merck pertaining to the commercial rights to pimicotinib, pursuant to which Merck is responsible for the commercialization of pimicotinib globally.

Outside of China, pimicotinib has been granted Breakthrough Therapy Designation by the US FDA and PRIME Designation by the European Medicines Agency ("**EMA**").

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd. is an oncology-focused biopharmaceutical company based in Shanghai that is dedicated to the discovery and development of innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich research & development and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of innovative programs focused on precision oncology and immuno-oncology.

Please visit www.abbisko.com for more information.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.